Docetaxel + Oxaliplatin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Transitional Cell Cancer of the Urothelial Tract
Conditions
Metastatic Transitional Cell Cancer of the Urothelial Tract
Trial Timeline
Dec 17, 2004 → Dec 2, 2009
NCT ID
NCT03159143About Docetaxel + Oxaliplatin
Docetaxel + Oxaliplatin is a phase 2 stage product being developed by Sanofi for Metastatic Transitional Cell Cancer of the Urothelial Tract. The current trial status is completed. This product is registered under clinical trial identifier NCT03159143. Target conditions include Metastatic Transitional Cell Cancer of the Urothelial Tract.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Transitional Cell Cancer of the Urothelial Tract were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03159143 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Transitional Cell Cancer of the Urothelial Tract